Aviceda, QUB to develop next-generation glyco-immune therapeutics
Pharmaceutical Technology
APRIL 10, 2023
Aviceda’s HALOS (high-affinity ligands of sigelcs) nanotechnology platform leverages glycobiology to modulate the innate immune system to develop advanced breakthrough therapeutics, focusing on immuno-oncology.
Let's personalize your content